GENSCRIPT BIOTECH CORPORATION |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 12.08 HKD | -2.42% |
|
+1.17% | -39.17% |
| May. 15 | Legend Expects to Log Profit in 2026 | MT |
| May. 14 | Legend Biotech's Loss Narrows in Q1 as Revenue Surges | MT |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Exceptional extension!
Take advantage of the offer
* See conditions on site
| Sales 2024 * | 1.27B 9.88B | Sales 2025 * | 1.91B 14.92B | Capitalization | 3.37B 26.3B |
|---|---|---|---|---|---|
| Net income 2024 * | -111M -866M | Net income 2025 * | 36M 281M | EV / Sales 2024 * | 2 x |
| Net cash position 2024 * | 840M 6.56B | Net cash position 2025 * | 664M 5.18B | EV / Sales 2025 * | 1.42 x |
| P/E ratio 2024 * |
-33.5
x | P/E ratio 2025 * |
62.9
x | Employees | 6,937 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 54.03% |
More Fundamentals
* Assessed data
More news
Latest transcript on Genscript Biotech Corporation
More press releases
| 1 day | -1.13% | ||
| 1 week | +2.51% | ||
| Current month | +5.15% | ||
| 1 month | +11.07% | ||
| 3 months | -11.94% | ||
| 6 months | -48.68% | ||
| Current year | -38.37% |
1 week
12.06
12.88
1 month
10.3813.10
Current year
10.3419.84
1 year
10.3424.95
3 years
10.3443.40
5 years
9.6643.40
10 years
1.0743.40
| Managers | Title | Age | Since |
|---|---|---|---|
Weihui Shao
CEO | Chief Executive Officer | - | 22-12-31 |
Ye Wang
FOU | Founder | 55 | 01-12-31 |
Shiniu Wei
DFI | Director of Finance/CFO | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Hong Xin Guo
BRD | Director/Board Member | 61 | 15-08-23 |
Li Zhu
BRD | Director/Board Member | 74 | 09-12-31 |
Yue Xin Pan
BRD | Director/Board Member | 65 | 15-08-23 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 1.61% | 4 M€ | -27.92% | ||
| 1.43% | 2 M€ | -12.23% | - | |
| 0.56% | 3 M€ | +10.86% | - | |
| 0.49% | 2 M€ | -.--% | ||
| 0.47% | 2 M€ | -14.14% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-20 | 12.08 | -2.42% | 10 691 446 |
| 24-05-17 | 12.38 | -0.64% | 10,698,000 |
| 24-05-16 | 12.46 | +0.32% | 16,581,560 |
| 24-05-14 | 12.42 | +4.02% | 19,528,040 |
| 24-05-13 | 11.94 | -4.94% | 24,374,300 |
Delayed Quote Hong Kong S.E., May 19, 2024 at 09:44 pm EDT
More quotes
Genscript Biotech Corporation is a Hong Kong-based investment holding company principally engaged in life science research and related businesses. The Company operates through four segments. Life Sciences Research Services segment includes gene and peptide synthesis, deoxyribonucleic acid (DNA) and primer synthesis, DNA sequencing, customized antibody production, protein expression and the production of stable cell lines. Preclinical Drug Development Services segment includes protein and antibody engineering, the study of in vitro drug and the study of in vivo drug. Life Sciences Research Catalog Products segment provides antibodies, recombinant proteins, equipment for protein isolation and analysis, molecular biology reagents, peptide, biochemicals and stable cell lines. Industrial Synthetic Biology Products segment is engaged in the development and production of industrial enzymes.
Calendar
2024-08-27
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
B
Sell
Buy
Mean consensus
BUY
Number of Analysts
13
Last Close Price
1.587
USD
Average target price
3.554
USD
Spread / Average Target
+123.99%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -38.37% | 3.37B | |
| +33.63% | 50.93B | |
| -0.09% | 42.12B | |
| +49.62% | 42.05B | |
| -4.96% | 29.18B | |
| +11.18% | 26.02B | |
| -21.95% | 18.9B | |
| +8.61% | 13.21B | |
| +24.73% | 12.17B | |
| +28.31% | 12.16B |
- Stock Market
- Equities
- 1548 Stock
